New paper using Attana Technology: A broadly potent antibody targeting the different Covid-19 mutations
The team of Prof Ali Salanti at University of Copenhagen has in a new publication identified a human monoclonal antibody from a health worker that has strong neutralizing capacity against the different Covid-19 mutations. The results using Attana technology once again confirms the importance of fast and persistent interaction between the antibody and the virus to obtain good neutralizing capacity and thereby good protection.
The relatively fast mutations of SARS-COV-2 virus is an issue both for vaccination and therapeutics. There is today no efficient treatment (no clinically authorized therapeutic antibodies) against the currently dominating mutations Omicron sub-lineages BA.2.86 and JN.1.
The Copenhagen team has isolated antibodies from a health care worker with proven good protection against SARS-COV-2 good. Some of these antibodies have high neutralizing capacity against all mutations.
Attanas immunity profiling has suggested that to have high neutralizing capacity, the interaction between the antibodies need to be fast and persistent. This is because it is a competition between the antibody and other sera molecules to interact with the spike protein of the virus. If the antibody is not fast enough, it takes too long time to block the virus and consequently the virus can infect cells in the body. It is also important that the interaction is persistent, that is once it has bound to the spike it stays. In actual numbers it has in several publications using Attana technology been shown that the association rate (how fast) need to be at least 10^5 per mol & s and the dissociation rate slower than 10^-4 per s to secure high neutralizing capacity.
Since Attana can measure these parameters using just a drop of blood, it means an easy and cost-efficient method to determine if individuals have good protection or need another extra booster dose of a vaccine to get a protection. It also means that when infectious outbreaks occur, healthy people can be rapidly scanned and potential therapeutical antibodies can be rapidly discovered.
For more information, please contact:
Teodor Aastrup, CEO
ir@attana.com
+46 708 86 23 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
About Attana
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com
Tags:
